Veloxis Pharmaceuticals A/S Reports Earnings Results for the First Quarter Ended March 31, 2017; Provides Earnings Guidance for the Year 2018
The company maintains its 2018 outlook of revenues to be in the range of USD 32 million to USD 40 million and operating loss before accounting for stock compensation in the range of USD 6 million to USD 12 million.